EP0112329A1 - Anti-tumour pharmaceutical preparation - Google Patents
Anti-tumour pharmaceutical preparationInfo
- Publication number
- EP0112329A1 EP0112329A1 EP19820901989 EP82901989A EP0112329A1 EP 0112329 A1 EP0112329 A1 EP 0112329A1 EP 19820901989 EP19820901989 EP 19820901989 EP 82901989 A EP82901989 A EP 82901989A EP 0112329 A1 EP0112329 A1 EP 0112329A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- drug
- metol
- hydroquinone
- pharmaceutical preparation
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Definitions
- the present invention will refer to a pharmaceutical to be used for the treatment of cancer, as well as other forms of tumors.
- cytostatics Endoxan, Saroolizine, Tio-tepa, Vincristin, Methotrexate, IOB 82, etc. (Vademecum terapeutic, Ed.med., 1973, subject).
- Ail such prenarations have some common disadvantages: they do not produce the complete regression of tumors or metastases, but only a temporary remission; they are highly toxic for the human body and, shortly after the treatment, they induce the so-called cytostatic disease with destructive effects upon the hemato ⁇ oietic System (leukopenia, tromocytopenia, haemorrhagipar syndrome, erythropenia, agranulocitosis), upon the digeetive apparatus (hypo or anachlorhydria, transient atrophy of the intestinal lymphatic System, melena, diarrhea), upon the nervous System (asthenia, cephalgia, insomnia, hallucinations, etc) upon the endocrine System (oligomenorrhea, atrophy of the uterus or of the tests, etc.), upon the mezenchyme (increase of capilaries permeability, intraparenchycje hemorrhages, etc.).
- cytostatic agents have general consequences upon the organisai such as loss of weight, hypotension, modification of humoral pH and ef oxygen consumption in the t issues, decrease of resistance to infections, etc.
- the pharmaceutical preparation as per the present invention increases the range of products for the treatment of cancer tumors; it is composed of 10 ... 350 mg hydroquinone, 30 ... 200 mg metol, 10 ... 100 mg amidol; the above-said three active ingredients may or not be associated with 10 ... 100 mg paraaminosalicylic acid; the quantities are expressed per unidose and the association, ratio (by weight) between hydroquinone and metol is between 1: 3 ... 7: 4.
- the drug is toxicity-free, in the doses recommended in the present invention
- Figures 1-3 illustrate the anti-tumor effect as well as s ome other aspects in c onnection the experime nta carried out on this preparation.
- composition, f or 1 dose, of the pharmaceutical preparation as per the prese nt invention is the following: Hydroquinone 23.5 mg
- composition is f ormulated as hard or s oft gelatine caps ules, for internal administration, using common adjuvants and the usual galenic technique.
- This drug can also be f ormulated as vaginal ovules and suppose itories, according to the type and localization of the disease.
- the composition may also be lyophilized in view of administration as injection or infusion.
- This drug is to be administered in one or several doses, according to the clinical c ondition of the patie nt, 15 to 30 minutes after a meal c ontaining proteins.
- the drug is to be added in tea or in stewed fruit at room temperature. After the intake of the medicine, the patie nt should not eat or drink anythiog for 1 hour, and a rest is to be recomme nded.
- a specify diet shall be recommended to each patie nt, according to his clinical condition and the stage of the disease.
- composition, for 1 dose, of the pharmaceutical preparation as per the inve ntion is the following:
- the drug is prepared and administered as described an Example 1.
- composition of the pharmaceutical product as per the invention is the following:
- the drug is prepared and administered as described under Example 1.
- composition of the pharmaceutical preparation as per the invention is the f ollowing:
- the drug is prepared and administered as described under Example 1.
- the compos ition of the pharmaceutical preparation as per the invention is the following:
- the drug is prepared and administered as described under Example 1.
- the humor and haematological parameters analyzed at the end of the chronic treatment were within the same limits as those of the healthy control animals (protein count, transaminases, cholesterol, total fluids, lipoproteins, glycemia).
- Figure 1 shows the inhibiting effect of one micromole of the preparation as per the invention and of one micromole of each active ingredient, as compared to guanazole as c ontrol.
- the graph in Fig. 1 illustrates the results obtained on laboratory animals with the substances marked by means of indicative izotopes. It can be noticed that each of the active ingredients has a specific inhibiting effect on 1210 leukemic ascitis and each of them is more active than the refere nce substances (guanazole); amidol low an activity of 32%, metol of 15% and hydroquinone of 13%.
- the graph indicates that the inhibiting effect of the mixture of ingredients is of 86.5%, which justifies their association through the mutual potentiation of their activities.
- Amidol both pote ntiates the effect of the other active ingredients and creates a biological bugfer medium, favorable to the activity of the drug.
- the treatment with the pharmaceutical preparation as per the invention may be associated with some other pharmaceutioals, such as: analgetios, general tonic agents, vitamins (with the exception of Vitamin B 12 in a quantity over 20 g / day). Mention must be made of the fact that the ass ociated pr oducts should be preferably administered 1/2 - 1 h after the administration of the preparation as per the present invention.
- the drug as per the invention since the drug as per the invention has a radios ensitizing action, it may be associated with radiotherapy thus increasing the effect of iradiation.
- the administration, during treatment, of infusion s olutions c ontaining amino-acids is not recomme nded.
- the above-mentioned examples for the composition of the drug as per the invention are not exclusive; within certain limits of dosage, several versions of the established composition may be used, depending upon the stage and 10-calization of the disease, the biological equilibrium of the organism and the tolerance of the organism.
Abstract
Mécicament destiné au traitement du cancer ou autres formes de tumeurs. Le médicament se compose de 10 à 350 mg d'hydroquinone, de 30 à 200 mg de métol, de 10 à 100 mg d'amidol; ces trois ingrédients actifs peuvent être associés à 10-100 mg d'acide paraminosalicilique ou peuvent ne pas l'être; les quantités sont exprimées par unidose et le rapport d'association (en poids) entre l'hydroquinone et le métol est compris entre 1:3 et 7:4. Le médicament n'est pas toxique dans les limites de dosage stipulées dans la présente invention.Medicament intended for the treatment of cancer or other forms of tumors. The drug consists of 10 to 350 mg of hydroquinone, 30 to 200 mg of metol, 10 to 100 mg of amidol; these three active ingredients may or may not be associated with 10-100 mg of paraminosalicilic acid; the quantities are expressed by single dose and the association ratio (by weight) between hydroquinone and metol is between 1: 3 and 7: 4. The drug is not toxic within the dosage limits stipulated in the present invention.
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RO1982/000004 WO1984000006A1 (en) | 1982-06-18 | 1982-06-18 | Anti-tumour pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0112329A1 true EP0112329A1 (en) | 1984-07-04 |
Family
ID=20094875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19820901989 Withdrawn EP0112329A1 (en) | 1982-06-18 | 1982-06-18 | Anti-tumour pharmaceutical preparation |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0112329A1 (en) |
WO (1) | WO1984000006A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997001333A1 (en) * | 1995-06-29 | 1997-01-16 | Liliana Leontopol | Synergistic medicinal anti-cancer composition having several para-substituted phenols |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2040183A (en) * | 1932-03-25 | 1936-05-12 | Ostro Res Lab Inc | Therapeutics for killing bacteria |
NL257911A (en) * | 1959-11-12 | |||
FR2244468A1 (en) * | 1973-07-31 | 1975-04-18 | Passwater Richard | Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids |
-
1982
- 1982-06-18 WO PCT/RO1982/000004 patent/WO1984000006A1/en not_active Application Discontinuation
- 1982-06-18 EP EP19820901989 patent/EP0112329A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO8400006A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1984000006A1 (en) | 1984-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100467060C (en) | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases | |
HU206987B (en) | Process for producing oral pharmaceutical compositions comprising alpha- or beta-interferon, suitable for reducing side effects of cancer therapy | |
US7528108B2 (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
RU2202361C2 (en) | Lectin-containing composites and their usage | |
KR20170003975A (en) | Curcumin-peptide conjugates and formulations thereof | |
US9655870B2 (en) | Homeopathic drug composition and methods of use thereof | |
US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
RU2214259C2 (en) | Lectin from robinia pseudoacacia and its application | |
EP0112329A1 (en) | Anti-tumour pharmaceutical preparation | |
US20100261663A1 (en) | Compositions Containing Harpagoside and Paeoniflorin and Methods for Treatment of Conditions Associated with Pain, Inflammation, Arthritis and Symptoms Thereof | |
WO2002038146A1 (en) | Mucosal immunomodulator and use thereof | |
RU2198673C2 (en) | Medicinal preparation for optimization of mucus viscosity and stimulation of intestine function | |
JP5291290B2 (en) | How to treat cancer patients undergoing chemotherapy | |
MXPA06003744A (en) | Use of extracts from the pelargonium species. | |
Abdi et al. | Combination of Fibroblast Interferon (HuIFNβ), Carboxamide (DTIC), and Cimetidine for Advanced Malignant Melanoma | |
AU2007361007A1 (en) | Immunopotentiating composition from labisia pumila extract | |
EP1666046A1 (en) | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis | |
BETHELL et al. | Cobalamin (vitamin B12) and the intrinsic factor of Castle | |
CA1168984A (en) | Antitumor compound | |
TWI673053B (en) | Use of echinacoside as ghrelin receptor agonist | |
KR20080009190A (en) | Compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients | |
JP2004513926A (en) | Preparations and methods for orally ingesting dwarf lectins. | |
Micans et al. | The Thymus gland, immune health and aging | |
RU2117435C1 (en) | Food restorative treatment-and-prophylactic additive | |
RU2120297C1 (en) | Method of normalization of metabolic processes in cell and a preparation for these aims |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE FR LI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CENTRALA INDUSTRIALA DE MEDICAMENTE, COSMETICE COL |
|
17P | Request for examination filed |
Effective date: 19840705 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19850823 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LEONTOPOL, ION MIHAI Inventor name: ANDRONESCU, NICOLAE |